Unichem Laboratories credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
469469430219297
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
17417431263.5110
0.17×0.17×0.18×0.09×0.12×
0.06×0.06×0.13×0.03×0.05×
2.55×2.55×1.62×2.19×−6.53×
0.76×0.95×1.18×0.63×−2.43×
1.87×1.87×6.67×−0.57×−9.18×
14.7%14.7%14.9%8.5%10.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

UNICHEMLAB₹488.80

Unichem Laboratories Limited

· Pharma & Health
₹ CrorePeersGUFICBIORPGLIFEGUJTHEMSMSPHARMAORCHPHARMAINDSWFTLABSOLARAFDCMcap ₹3,441 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt297.4219.1430.0468.8468.8
Net Debt110.563.5312.3174.1174.1
Total Debt/Equity0.120.090.180.170.17
Net Debt/Equity0.050.030.130.060.06
Total Debt/EBITDA-6.532.191.622.552.55
Net Debt/EBITDA-2.430.631.180.950.76
Interest Coverage (EBIT/Interest)-9.18-0.576.671.871.87
Total Debt/Total Capital %10.888.4914.9314.7114.71
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.